Cryoport Generates Strong Interest for Its Cryogenic Logistics Solution for Reproductive Medicine

LAKE FOREST, Calif.--(BUSINESS WIRE)-- Cryoport, Inc. (OTCBB: CYRX) recently showcased its Cryoport Express® logistics solutions during the 29th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in London. This critical meeting was the kickoff for Cryoport’s expanded presence within the EU reproductive medicine arena.

“The international and European markets are important underserved markets,” said Steve Leatherman, Cryoport’s Chief Commercial Officer. “There are no competitors in this space that match Cryoport’s value proposition. Our turnkey solution provides both clinics and patients with an economic, proven and unmatched solution. As a proof point, the ESHRE meeting alone that was attended by our London-based EU Commercial Director generated leads from over 50 countries further emphasizing the international demand for Cryoport’s solution.”

Cryoport started aggressively targeting reproductive medicine with its turnkey cryogenic logistics solution in early 2012 resulting in positive business growth every quarter since. Despite typical summer downturns within the logistics arena, Cryoport reported record shipments in July of 2013.

“It is clear that our solutions are well positioned to capture significant market share in this growing market,” Cryoport President and CEO Jerrell Shelton stated. “Our sales and marketing initiatives targeted at the reproductive medicine market, in-vitro-fertilization in particular, are starting to ramp and open up new opportunities. We have now developed the strong in-house logistics expertise necessary for this market and our customers are impressed by the depth of cold chain logistics expertise Cryoport is bringing to the table.”

About Cryoport, Inc.

Cryoport provides leading edge frozen shipping logistics solutions to the biotechnology and life science industries through the combination of purpose built proprietary hardware and software technologies and skilled total turnkey management of the entire logistics process. Cryoport Express® liquid nitrogen dry vapor shippers are validated to maintain a constant -150°C temperature for a 10 plus day dynamic shipment duration, and its Cryoportal™ Logistics Management Platform manages the entire shipment process, including initial order input, document preparation, customs clearance, courier management, shipment tracking, issue resolution, and delivery. Cryoport’s total turnkey logistics solutions offer reliability, cost effectiveness, and convenience, while the use of recyclable and reusable components provides a “green” and environmentally friendly solution. Cryoport service options include recording the “chain of condition” and “chain of custody” for all shipments thereby meeting the exacting requirements for scientific work and for regulatory purposes. For more information visit

Forward Looking Statements

Statements in this press release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Cryoport, Inc.
Robert Stefanovich, 619.481.6802

Source: Cryoport, Inc.